Keiko Yanai, Junpei Ito, M. Nakahira, Yuichiro Enoki, M. Sugasawa
{"title":"Utility of ultrasound sonography to assess the upward distance moved by the hyoid bone during saliva swallowing: a study of healthy volunteers","authors":"Keiko Yanai, Junpei Ito, M. Nakahira, Yuichiro Enoki, M. Sugasawa","doi":"10.5981/jjhnc.48.351","DOIUrl":"https://doi.org/10.5981/jjhnc.48.351","url":null,"abstract":"","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71244044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Co. Nivolumab, an immune checkpoint inhibitor, was approved for the treatment of “recurrent or metastatic head and neck cancer” in March 2017 in Japan. This approval was based on the results of a global phase 3 clinical trial, the CheckMate 141 trial, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In the 4 years after its approval, multiple Japanese research institutions have reported real-world data of nivolumab, elucidating the further treatment outcomes of nivolumab. In this article, we review published litera-ture reporting real-world outcomes of nivolumab, focusing on: （1） long-term follow-up, （2） patients with primary sites who were excluded from the CheckMate 141 trial, and （3） salvage chemotherapy following nivolumab treatment.
{"title":"Real world evidence of nivolumab in Japanese patients with head and neck cancer","authors":"A. Homma, Hirokazu Kaneko, Toshimitsu Endo","doi":"10.5981/jjhnc.48.1","DOIUrl":"https://doi.org/10.5981/jjhnc.48.1","url":null,"abstract":"Co. Nivolumab, an immune checkpoint inhibitor, was approved for the treatment of “recurrent or metastatic head and neck cancer” in March 2017 in Japan. This approval was based on the results of a global phase 3 clinical trial, the CheckMate 141 trial, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In the 4 years after its approval, multiple Japanese research institutions have reported real-world data of nivolumab, elucidating the further treatment outcomes of nivolumab. In this article, we review published litera-ture reporting real-world outcomes of nivolumab, focusing on: （1） long-term follow-up, （2） patients with primary sites who were excluded from the CheckMate 141 trial, and （3） salvage chemotherapy following nivolumab treatment.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71243929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although elective neck dissection （END） for early oral squamous cell carcinoma （OSCC） has low morbidity and mortality and is recommended as a treatment strategy, it is inevitable due to the nature of the procedure and many surgeries are performed unnecessarily. In Europe and the United States, sentinel node navigation surgery （SNNS） has been explored in clinical trials as a tool for managing early OSCC, which may help avoid unnecessary END. In Japan, we have encouraged the clinical use of SNNS in a domestic multi-institutional joint research. A phase Ⅲ randomized trial including 271 OSCC cases, which aimed to compare SNNS with END, found that the overall and disease-free survival rates did not differ, and the scores of neck functionality in the SNNS group were significantly better. It is anticipated that as the concept of SNNS becomes more widespread in the future, it will be necessary to subdivide micrometastases.
{"title":"Sentinel node navigation surgery as a diagnosis and treatment tool to find occult metastasis for early oral cancer","authors":"T. Matsuzuka, Y. Hasegawa","doi":"10.5981/jjhnc.48.257","DOIUrl":"https://doi.org/10.5981/jjhnc.48.257","url":null,"abstract":"Although elective neck dissection （END） for early oral squamous cell carcinoma （OSCC） has low morbidity and mortality and is recommended as a treatment strategy, it is inevitable due to the nature of the procedure and many surgeries are performed unnecessarily. In Europe and the United States, sentinel node navigation surgery （SNNS） has been explored in clinical trials as a tool for managing early OSCC, which may help avoid unnecessary END. In Japan, we have encouraged the clinical use of SNNS in a domestic multi-institutional joint research. A phase Ⅲ randomized trial including 271 OSCC cases, which aimed to compare SNNS with END, found that the overall and disease-free survival rates did not differ, and the scores of neck functionality in the SNNS group were significantly better. It is anticipated that as the concept of SNNS becomes more widespread in the future, it will be necessary to subdivide micrometastases.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71244031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We report a rare case of intravascular solitary fibrous tumor （SFT） from the internal jugular vein to the sigmoid sinus, which has been followed over nine years. A 51-year-old woman was referred to our hospital, pre-senting with fullness of the right ear and swelling of the right neck. On imaging study, a tumor occupying from the right supraclavicular to the skull base, through the jugular foramen was found. The biopsy specimen of the intravascular tumor of the right jugular vein was initially diagnosed as epithelioid hemangioendothelioma （EHE）. The tumor increased in size at first, and after two courses of S-1 therapy （Tegafur, a prodrug of 5-fluorouracil, and 5-chloro-2-4-dihydroxypyridine）, the intravascular tumor in the right jugular vein had disappeared, whereas the lesion at the skull base remained stationary. This remaining lesion had gradually enlarged over the next 3—4 years, causing Ⅶ—Ⅻ cranial nerve paralysis. Radiation therapy was administered, and arytenoid adduc-tion and nerve-muscle pedicle flap implantation were performed for laryngeal paralysis. Over 5-year follow-up observation after irradiation, the remaining lesion at the skull base gradually diminished each year. Afterward, the histopathological findings of the biopsy specimen were reviewed and a revised diagnosis of intravascular SFT was made. Intravascular SFT is extremely rare, and the effects of chemotherapy or radiotherapy for a malignant soft tissue tumor are controversial, however, S-1 therapy and radiation therapy were successful in this case.
{"title":"A rare case of intravascular solitary fibrous tumor from the internal jugular vein to the sigmoid sinus","authors":"M. Masuda, Y. Honda, Daizo Murakami, Y. Orita","doi":"10.5981/jjhnc.48.40","DOIUrl":"https://doi.org/10.5981/jjhnc.48.40","url":null,"abstract":"We report a rare case of intravascular solitary fibrous tumor （SFT） from the internal jugular vein to the sigmoid sinus, which has been followed over nine years. A 51-year-old woman was referred to our hospital, pre-senting with fullness of the right ear and swelling of the right neck. On imaging study, a tumor occupying from the right supraclavicular to the skull base, through the jugular foramen was found. The biopsy specimen of the intravascular tumor of the right jugular vein was initially diagnosed as epithelioid hemangioendothelioma （EHE）. The tumor increased in size at first, and after two courses of S-1 therapy （Tegafur, a prodrug of 5-fluorouracil, and 5-chloro-2-4-dihydroxypyridine）, the intravascular tumor in the right jugular vein had disappeared, whereas the lesion at the skull base remained stationary. This remaining lesion had gradually enlarged over the next 3—4 years, causing Ⅶ—Ⅻ cranial nerve paralysis. Radiation therapy was administered, and arytenoid adduc-tion and nerve-muscle pedicle flap implantation were performed for laryngeal paralysis. Over 5-year follow-up observation after irradiation, the remaining lesion at the skull base gradually diminished each year. Afterward, the histopathological findings of the biopsy specimen were reviewed and a revised diagnosis of intravascular SFT was made. Intravascular SFT is extremely rare, and the effects of chemotherapy or radiotherapy for a malignant soft tissue tumor are controversial, however, S-1 therapy and radiation therapy were successful in this case.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71244051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Fujimoto, T. Shinozaki, Toshifumi Tomioka, W. Okano, Y. Morishita, R. Hayashi, K. Matsuura
Enhanced Recovery After Surgery （ERAS） is a package of various evidence-based perioperative management methods that enhance the quality of postoperative recovery. The Japanese version of the Quality of Recovery score （QoR-40J） is a clinical outcome which is widely used to evaluate the quality of recovery after surgery under general anesthesia. We evaluated the quality of recovery using the QoR-40J in 10 patients who had been managed according to our ERAS protocol for head and neck surgery followed by free tissue transfer reconstruction. We were able to conduct the ERAS protocol safely and to obtain QoR-40J scores in all patients. The mean overall score of QoR-40J significantly decreased from the day before surgery to postoperative-day （POD） 1, and tended to recover gradually from POD 2 to POD 7. It was suggested that the score trends of QoR-40J reflected the quality of recovery after head and neck surgery followed by free tissue transfer reconstruction. We would like to use the QoR-40J as an indicator to improve perioperative management and to construct a new standard of the ERAS protocol for head and neck surgery.
ERAS (Enhanced Recovery After Surgery)是一套多种循证围手术期管理方法，可提高术后恢复质量。日本版QoR-40J恢复质量评分(Quality of Recovery score, QoR-40J)是广泛用于评价全麻手术后恢复质量的临床指标。我们使用QoR-40J评估了10例患者的恢复质量，这些患者按照我们的ERAS方案进行了头颈部手术，随后进行了自由组织移植重建。我们能够安全地进行ERAS方案，并获得所有患者的QoR-40J评分。QoR-40J平均总分从术前1天至术后1天(POD)显著下降，从POD 2天至POD 7天逐渐恢复。提示QoR-40J评分趋势反映了头颈部手术后游离组织移植重建的恢复质量。我们希望以QoR-40J为指标，提高围手术期的管理水平，为头颈部外科ERAS方案建立新的标准。
{"title":"ERAS protocol for head and neck surgery and quality assessment of postoperative recovery","authors":"S. Fujimoto, T. Shinozaki, Toshifumi Tomioka, W. Okano, Y. Morishita, R. Hayashi, K. Matsuura","doi":"10.5981/jjhnc.48.268","DOIUrl":"https://doi.org/10.5981/jjhnc.48.268","url":null,"abstract":"Enhanced Recovery After Surgery （ERAS） is a package of various evidence-based perioperative management methods that enhance the quality of postoperative recovery. The Japanese version of the Quality of Recovery score （QoR-40J） is a clinical outcome which is widely used to evaluate the quality of recovery after surgery under general anesthesia. We evaluated the quality of recovery using the QoR-40J in 10 patients who had been managed according to our ERAS protocol for head and neck surgery followed by free tissue transfer reconstruction. We were able to conduct the ERAS protocol safely and to obtain QoR-40J scores in all patients. The mean overall score of QoR-40J significantly decreased from the day before surgery to postoperative-day （POD） 1, and tended to recover gradually from POD 2 to POD 7. It was suggested that the score trends of QoR-40J reflected the quality of recovery after head and neck surgery followed by free tissue transfer reconstruction. We would like to use the QoR-40J as an indicator to improve perioperative management and to construct a new standard of the ERAS protocol for head and neck surgery.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71244065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Makiko Kodani, S. Koyama, Tsuyoshi Morisaki, T. Fukuhara, K. Fujiwara, H. Takeuchi, H. Kataoka
Chemoradiotherapy for head and neck cancer （HNC） causes various adverse events, among which weight loss is a major concern. Methodologies for the prevention and care of adverse events have not yet been standardized; therefore, we created a clinical pathway （CP） as a tool for standardized assessment and care. In this study, we assessed whether CP is useful in weight loss reduction during chemoradiotherapy for HNC. We retrospectively analyzed 108 patients who underwent treatment with high-dose cisplatin concurrent with radiotherapy （CRT） and cetuximab concurrent with radiotherapy （BRT） from January 2014 to March 2020. We stratified the patients into those with and without a CP. In CRT, the maximum weight loss rate was not significantly reduced in the CP-use group; however, aggravation of oral mucositis was suppressed in the CP-use group （p ＝ 0.043）. In BRT, the maximum weight loss rate was significantly reduced in the CP-use group compared with the non-use group （p ＝ 0.011）, and oral mucositis was equally suppressed in the CP-use group （p ＝ 0.037）. We believe that in BRT, using CP is effective in the weight loss reduction that occurs during the treatment.
{"title":"Usefulness of clinical pathway in weight loss reduction during chemoradiotherapy for head and neck cancer","authors":"Makiko Kodani, S. Koyama, Tsuyoshi Morisaki, T. Fukuhara, K. Fujiwara, H. Takeuchi, H. Kataoka","doi":"10.5981/jjhnc.47.303","DOIUrl":"https://doi.org/10.5981/jjhnc.47.303","url":null,"abstract":"Chemoradiotherapy for head and neck cancer （HNC） causes various adverse events, among which weight loss is a major concern. Methodologies for the prevention and care of adverse events have not yet been standardized; therefore, we created a clinical pathway （CP） as a tool for standardized assessment and care. In this study, we assessed whether CP is useful in weight loss reduction during chemoradiotherapy for HNC. We retrospectively analyzed 108 patients who underwent treatment with high-dose cisplatin concurrent with radiotherapy （CRT） and cetuximab concurrent with radiotherapy （BRT） from January 2014 to March 2020. We stratified the patients into those with and without a CP. In CRT, the maximum weight loss rate was not significantly reduced in the CP-use group; however, aggravation of oral mucositis was suppressed in the CP-use group （p ＝ 0.043）. In BRT, the maximum weight loss rate was significantly reduced in the CP-use group compared with the non-use group （p ＝ 0.011）, and oral mucositis was equally suppressed in the CP-use group （p ＝ 0.037）. We believe that in BRT, using CP is effective in the weight loss reduction that occurs during the treatment.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71243521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Investigation of parotid gland cancer surgery that preserved the facial nerve","authors":"Ryoki Hamabata, N. Mukoyama, N. Nishio, T. Maruo, M. Hiramatsu, S. Yokoi, M. Sone, Yasushi Fujimoto","doi":"10.5981/jjhnc.47.316","DOIUrl":"https://doi.org/10.5981/jjhnc.47.316","url":null,"abstract":"要 旨 顔面神経を温存した耳下腺癌手術症例の,術後の顔面神経麻痺の推移と予後の関係を検討した報告は少な い。当科の耳下腺癌の治療方針は,術前から顔面神経麻痺がある場合は神経合併切除と一期的再建,麻痺がな い場合は組織型にかかわらず原則温存としている。過去 15 年間の顔面神経を温存した耳下腺癌手術症例 31 例 について検討した。観察期間中央値は 60 ヶ月,全摘 24 例,葉切除が 7 例であった。手術直後の顔面神経麻痺 スコアは平均 24 点,中央値は 27 点であった。術後顔面神経麻痺の推移は,一過性に完全麻痺の症例もあった が,最終的に平均 39.5 点まで回復した。回復期間は多くの症例が術後 6 ヶ月までに回復した。治療成績は,5 年全生存率・5 年無病生存率・局所制御率それぞれ 96.0%・89.5%・93.5%と良好な結果であった。術前顔面 神経麻痺のない耳下腺癌症例は,病理型に関わらず神経を温存しても治療成績は担保されると考える。","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71243548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Musha, Nobuteru Kubo, N. Okano, T. Kaminuma, H. Kawamura, Hiro Sato, Y. Takayasu, M. Shino, O. Nikkuni, Shota Ida, K. Shirai, J. Saitoh, M. Ogawa, S. Yokoo, K. Chikamatsu, T. Ohno
of the head and neck in 35 patients enrolled in a pective study at the Gunma University Heavy Ion Medical Center （from 2010 to 2014）. The median age of the patients was 59 years （range, 31-77 years）. The median follow-up time for all the patients was 65 months （range, 6.1-98.8 months）. Thirty-two and three patients received 64.0 Gy （relative biological effectiveness） and 57.6 Gy （relative biological effectiveness） in 16 fractions, respectively. The T-classification was 5/8/22 in T2/3/4, respectively, and the tumors were inoperable in 20 cases （57％）. The maxillary sinus and nasal cavity were the most common sites for tumors in 9 cases （26％）. Adenoid cystic carcinoma was dominant, with this carcinoma being found in 21 cases （60％）. The 5-year local control, progression-free survival, and overall survival rates were 74.5％, 53.2％, and 81.3％, respectively. Nine patients had local recurrence, and six patients died. Acute and late adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0. Over acute grade 3 radiation mucositis （8 cases） improved immediately with conservative therapy. Late grade 4 adverse events were observed; these were two cases of visual loss and one case of brain necrosis. There were no grade 5 adverse events. Carbon-ion radiotherapy achieved excellent local control and overall survival rates for non-squamous cell carcinoma.
{"title":"Prospective observational study of patients treated with carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck in Gunma University","authors":"A. Musha, Nobuteru Kubo, N. Okano, T. Kaminuma, H. Kawamura, Hiro Sato, Y. Takayasu, M. Shino, O. Nikkuni, Shota Ida, K. Shirai, J. Saitoh, M. Ogawa, S. Yokoo, K. Chikamatsu, T. Ohno","doi":"10.5981/JJHNC.47.53","DOIUrl":"https://doi.org/10.5981/JJHNC.47.53","url":null,"abstract":"of the head and neck in 35 patients enrolled in a pective study at the Gunma University Heavy Ion Medical Center （from 2010 to 2014）. The median age of the patients was 59 years （range, 31-77 years）. The median follow-up time for all the patients was 65 months （range, 6.1-98.8 months）. Thirty-two and three patients received 64.0 Gy （relative biological effectiveness） and 57.6 Gy （relative biological effectiveness） in 16 fractions, respectively. The T-classification was 5/8/22 in T2/3/4, respectively, and the tumors were inoperable in 20 cases （57％）. The maxillary sinus and nasal cavity were the most common sites for tumors in 9 cases （26％）. Adenoid cystic carcinoma was dominant, with this carcinoma being found in 21 cases （60％）. The 5-year local control, progression-free survival, and overall survival rates were 74.5％, 53.2％, and 81.3％, respectively. Nine patients had local recurrence, and six patients died. Acute and late adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0. Over acute grade 3 radiation mucositis （8 cases） improved immediately with conservative therapy. Late grade 4 adverse events were observed; these were two cases of visual loss and one case of brain necrosis. There were no grade 5 adverse events. Carbon-ion radiotherapy achieved excellent local control and overall survival rates for non-squamous cell carcinoma.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71243582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A case of laryngeal adenosquamous carcinoma manifesting as a submucosal tumor","authors":"Dai Hashimoto","doi":"10.5981/jjhnc.47.395","DOIUrl":"https://doi.org/10.5981/jjhnc.47.395","url":null,"abstract":"","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71243487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：